RECURRENT SALIVARY GLAND CARCINOMA
Clinical trials for RECURRENT SALIVARY GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT SALIVARY GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT SALIVARY GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hormone cocktail shows promise for rare salivary cancer
Disease control OngoingThis phase 2 trial is testing two hormone-blocking drugs—darolutamide and leuprolide acetate—in 21 patients with advanced salivary gland cancer that has spread or returned. The cancer must have a protein called androgen receptor. The goal is to see if the combination can shrink t…
Matched conditions: RECURRENT SALIVARY GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for rare salivary gland cancer
Disease control OngoingThis study tests a combination of two drugs—pemetrexed (chemotherapy) and pembrolizumab (immunotherapy)—in people with salivary gland cancer that has returned or spread. The goal is to see if this combo can shrink tumors or slow the disease. About 45 adults with advanced salivary…
Matched conditions: RECURRENT SALIVARY GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.
Matched conditions: RECURRENT SALIVARY GLAND CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC